Colorectal cancer (CRC) is the second most common cause of cancer death in the USA. Current research is shifting the focus from chemotherapy to chemoprevention wherein the latter is rapidly emerging as a strategy to avert colon cancer. Recently, aspirin has received attention as a chemopreventive agent as it shows significant effects in reducing the incidence of CRC. Thus, the overall goal was to develop novel nanoparticle-based colon targeted formulations of aspirin using various polymers. These nanoparticle formulations were assessed for process development, particle size, encapsulation efficiency, total yield and in vitro release kinetics with the ultimate goal of developing an effective nanotechnology-based colon-targeting delivery system to prevent colorectal cancer (CRC).
展开▼
